Cannabis Law Report
MARCH 23, 2022
Psychedelic medicine could provide much needed treatment options for some mental health and neurological disorders in the near future. There are a number of differences between PAP and current treatment approaches. This is because of the status of psychedelics as Schedule 1 drugs, under the Misuse of Drugs Regulations 2001.
Cannabis Law Report
SEPTEMBER 22, 2021
This change would mean it would be easier to run trials on its use in mental health treatments. The Prime Minister had already approved the rescheduling of psilocybin for exploring its potential as a treatment for depression, which he informed Mr Blunt in a meeting in May. Source: [link].
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Cannigma
MAY 19, 2021
In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes. CBD has become especially trendy in Tokyo, where CBD shops and cafes allow for the on-site consumption of CBD in edibles and topical treatments.
CannaMD
AUGUST 26, 2020
Current Cocaine Treatments. As researchers point out: There is no gold standard pharmacological treatment for dependence on cocaine. Although several drugs have been investigated, there is no strong or consistent evidence indicating any of these drugs for the treatment of cocaine use disorder. mice/rats).
CannaTech
SEPTEMBER 16, 2018
Canada has been at the forefront of shaping much of the rhetoric surrounding cannabis since 2001. Over time extended clinical trials will continue to map out the plant’s therapeutic effects, supporting it as an alternative medicine offering relief for a long list of conditions. Changing Cannabis Conversations Worldwide.
Cannabis Law Report
MARCH 1, 2019
Natalie has worked with private hospitals and clinics in relation to medical malpractice claims, and assisted on cases involving medical devices product liability and clinical trials. Acting on a broad range of cases, all with a medical or injury element, usually on the instructions of insurers. Legalisation. The Reality.
Otherside Farms
JANUARY 23, 2019
Differential effects of repeated low dose treatment with the cannabinoid agonist WIN 55,212-2 in experimental models of bone cancer pain and neuropathic pain. cancer cells (full – 2001). Inhibition of Glioma Growth in Vivo by Selective Activation of the CB2 Cannabinoid Receptor1 (full – 2001). full – 2001).
Expert insights. Personalized for you.
52 
Let's personalize your content